Data from 68 patients (target of 324) on the paxalisib-ONC201 combo shows mOS of 16.5 months vs. 9-12 months in historical control:
https://academic.oup.com/neuro-oncology/article-abstract/25/Supplement_5/v97/7405821?redirectedFrom=fulltext
Further evidence on this treatment combination outside of the PNOC trial with even more impressive mOS results:
https://academic.oup.com/neuro-oncology/article-abstract/25/Supplement_5/v232/7406650
